PL3388420T3 - Związki chinolinowe, sposób ich wytwarzania i ich zastosowanie jako leku stanowiącego inhibitor transportera anionu kwasu moczowego - Google Patents
Związki chinolinowe, sposób ich wytwarzania i ich zastosowanie jako leku stanowiącego inhibitor transportera anionu kwasu moczowegoInfo
- Publication number
- PL3388420T3 PL3388420T3 PL16872373.2T PL16872373T PL3388420T3 PL 3388420 T3 PL3388420 T3 PL 3388420T3 PL 16872373 T PL16872373 T PL 16872373T PL 3388420 T3 PL3388420 T3 PL 3388420T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- quinoline compounds
- transporter inhibitor
- inhibitor drug
- urate transporter
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510896887 | 2015-12-07 | ||
| PCT/CN2016/108688 WO2017097182A1 (zh) | 2015-12-07 | 2016-12-06 | 喹啉类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3388420T3 true PL3388420T3 (pl) | 2022-12-05 |
Family
ID=59013742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16872373.2T PL3388420T3 (pl) | 2015-12-07 | 2016-12-06 | Związki chinolinowe, sposób ich wytwarzania i ich zastosowanie jako leku stanowiącego inhibitor transportera anionu kwasu moczowego |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10450274B2 (pl) |
| EP (1) | EP3388420B1 (pl) |
| JP (1) | JP6752888B2 (pl) |
| CN (2) | CN106831570B (pl) |
| AU (1) | AU2016368240B2 (pl) |
| BR (1) | BR112018011390B1 (pl) |
| CA (1) | CA3007783C (pl) |
| DK (1) | DK3388420T3 (pl) |
| ES (1) | ES2926781T3 (pl) |
| HU (1) | HUE059672T2 (pl) |
| PL (1) | PL3388420T3 (pl) |
| PT (1) | PT3388420T (pl) |
| RU (1) | RU2715229C2 (pl) |
| TW (1) | TWI744264B (pl) |
| WO (1) | WO2017097182A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110452168B (zh) * | 2018-05-07 | 2022-03-15 | 中国医学科学院药物研究所 | N-苯基-n-喹啉羧酸类化合物及其制法和药物用途 |
| CN110467571B (zh) * | 2018-05-11 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 一种制备环烷基甲酸类衍生物或其可药用盐的方法 |
| CN108853112B (zh) * | 2018-06-13 | 2021-02-02 | 四川理工学院 | 化合物或其在药学上可接受的盐在制备治疗痛风、高尿酸血症药物中的应用 |
| AU2019370062A1 (en) * | 2018-11-02 | 2021-05-20 | Jiangsu Hengrui Medicine Co., Ltd. | Joint use of compound a and compound B in preparation of medications for treatment of gout or hyperuricemia |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| WO2021262596A1 (en) | 2020-06-22 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
| CN113559074B (zh) * | 2020-06-28 | 2023-04-21 | 海创药业股份有限公司 | 一种喹啉类化合物缓释片及其制备方法 |
| CN114315705B (zh) * | 2020-09-29 | 2024-02-20 | 杭州中美华东制药有限公司 | 一类urat1抑制剂及其制备方法与用途 |
| CN114621136B (zh) * | 2020-12-09 | 2023-11-07 | 江苏正大清江制药有限公司 | 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用 |
| CN115385854B (zh) * | 2021-05-19 | 2024-04-09 | 江苏正大清江制药有限公司 | 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用 |
| CA3232088A1 (en) * | 2021-09-17 | 2023-03-23 | Hinova Pharmaceuticals Inc. | Quinoline compound sustained-release tablet and preparation method thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2096140A (en) * | 1937-10-19 | Unsymmetkical indigoid dyesttjffs | ||
| US2568037A (en) * | 1947-10-24 | 1951-09-18 | Sterling Drug Inc | Tertiary-aminoalkyl esters and amides of 4-quinolylmercaptoalkanoic acids and their preparation |
| CA2251580A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amides as npy5 receptor antagonists |
| SA04250253B1 (ar) * | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| DE10348023A1 (de) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| US7786139B2 (en) * | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| EP2396003B1 (en) * | 2009-02-12 | 2013-04-17 | ArQule, Inc. | A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib |
| EP2521724B1 (en) * | 2009-12-11 | 2016-11-23 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
| AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| EP2651404B1 (en) * | 2010-12-14 | 2015-10-14 | Electrophoretics Limited | Casein kinase 1delta (ck1delta) inhibitors |
| ES2668721T3 (es) * | 2013-05-13 | 2018-05-21 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Derivado de ácido de cicloalquilo, método de preparación y aplicación farmacéutica del mismo |
-
2016
- 2016-12-06 WO PCT/CN2016/108688 patent/WO2017097182A1/zh active Application Filing
- 2016-12-06 CN CN201611109006.8A patent/CN106831570B/zh active Active
- 2016-12-06 AU AU2016368240A patent/AU2016368240B2/en active Active
- 2016-12-06 PT PT168723732T patent/PT3388420T/pt unknown
- 2016-12-06 PL PL16872373.2T patent/PL3388420T3/pl unknown
- 2016-12-06 JP JP2018529587A patent/JP6752888B2/ja active Active
- 2016-12-06 EP EP16872373.2A patent/EP3388420B1/en active Active
- 2016-12-06 BR BR112018011390-5A patent/BR112018011390B1/pt active IP Right Grant
- 2016-12-06 CA CA3007783A patent/CA3007783C/en active Active
- 2016-12-06 HU HUE16872373A patent/HUE059672T2/hu unknown
- 2016-12-06 RU RU2018120242A patent/RU2715229C2/ru active
- 2016-12-06 US US15/781,997 patent/US10450274B2/en active Active
- 2016-12-06 ES ES16872373T patent/ES2926781T3/es active Active
- 2016-12-06 CN CN201611109936.3A patent/CN106831569B/zh active Active
- 2016-12-06 DK DK16872373.2T patent/DK3388420T3/da active
- 2016-12-07 TW TW105140365A patent/TWI744264B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE059672T2 (hu) | 2022-12-28 |
| CA3007783C (en) | 2021-06-08 |
| RU2715229C2 (ru) | 2020-02-26 |
| PT3388420T (pt) | 2022-09-20 |
| JP6752888B2 (ja) | 2020-09-09 |
| CN106831570B (zh) | 2020-03-31 |
| EP3388420B1 (en) | 2022-06-22 |
| RU2018120242A (ru) | 2020-01-09 |
| WO2017097182A1 (zh) | 2017-06-15 |
| CN106831569B (zh) | 2020-07-17 |
| AU2016368240B2 (en) | 2020-01-02 |
| EP3388420A4 (en) | 2019-05-22 |
| ES2926781T3 (es) | 2022-10-28 |
| US20180362466A1 (en) | 2018-12-20 |
| TWI744264B (zh) | 2021-11-01 |
| JP2019502673A (ja) | 2019-01-31 |
| CN106831570A (zh) | 2017-06-13 |
| BR112018011390A2 (pt) | 2018-12-04 |
| TW201720797A (zh) | 2017-06-16 |
| AU2016368240A1 (en) | 2018-06-28 |
| EP3388420A1 (en) | 2018-10-17 |
| RU2018120242A3 (pl) | 2020-01-09 |
| CN106831569A (zh) | 2017-06-13 |
| DK3388420T3 (da) | 2022-09-26 |
| BR112018011390B1 (pt) | 2024-01-09 |
| CA3007783A1 (en) | 2017-06-15 |
| US10450274B2 (en) | 2019-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1255566A1 (zh) | 氧代吡啶酰胺類衍生物、其製備方法及其在醫藥上的應用 | |
| IL256085B (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment | |
| HUE054964T2 (hu) | Pirazol-heteroaril készítmény, az elõállítás módja és gyógyászati felhasználása | |
| PT3388420T (pt) | Compostos de quinolina, método de preparação dos mesmos e uso dos mesmo como fármaco inibidor do transportador de urato | |
| HK1231377A1 (zh) | 包含喹啉衍生物或其鹽的藥物組合物及其製備方法 | |
| IL259711A (en) | Methods for the preparation of protein kinase inhibitors and their medical use | |
| HK1243999A1 (zh) | 新型3-吲哚取代的衍生物、藥物組合物及使用方法 | |
| EP3524603A4 (en) | FGFR4 INHIBITOR, PRODUCTION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | |
| EP3299369A4 (en) | Pyrido-azaheterecydic compound and preparation method and use thereof | |
| IL250524B (en) | Carboxylic acid compound, method for its preparation and use | |
| EP3369734A4 (en) | KINASEINHIBITOR AND METHOD OF PREPARATION AND PHARMACEUTICAL USE THEREOF | |
| HK1244808A1 (zh) | 苯並哌啶類衍生物、其製備方法及其在醫藥上的應用 | |
| EP3115361A4 (en) | Heterocyclic compounds, and preparation method and use thereof | |
| EP3231802A4 (en) | Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof | |
| EP3327014A4 (en) | Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof | |
| EP3438105A4 (en) | DIARYL-BETA-LACTAM COMPOUND AND METHOD OF MANUFACTURE AND PHARMACEUTICAL USE THEREOF | |
| EP3181553A4 (en) | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | |
| HK1256362A1 (zh) | 共晶、其製造方法及含有共晶的藥物 | |
| EP3381919A4 (en) | Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof | |
| HK1246279A1 (zh) | C14-位羥基酯化的雷公藤甲素氨基酸衍生物、及其製備方法和應用 | |
| EP3130340A4 (en) | Isoacteoside derivative and preparation method and use thereof | |
| EP3388433A4 (en) | PHTHALAZINE DERIVATIVE AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| EP3354648A4 (en) | 4-SUBSTITUTED CUMARINE DERIVATIVE AND METHOD OF PREPARATION AND USE THEREOF | |
| EP3243823A4 (en) | Mangiferin-6-o-berberine salt and preparation method and use thereof | |
| EP3284743A4 (en) | Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof |